Selective Destruction Of Cells Infected With The Human Immunodeficiency Virus
- Idaho Falls, ID
Compositions and methods for selectively killing a cell containing a viral protease are disclosed. The composition is a varient of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between the A and B chains. The variant of the type II ribosome-inactivating protein is activated by digestion of the viral protease cleavage site by the specific viral protease. The activated ribosome-inactivating protein then kills the cell by inactivating cellular ribosomes. A preferred embodiment of the invention is specific for human immunodeficiency virus (HIV) and uses ricin as the ribosome-inactivating protein. In another preferred embodiment of the invention, the variant of the ribosome-inactivating protein is modified by attachment of one or more hydrophobic agents. The hydrophobic agent facilitates entry of the variant of the ribosome-inactivating protein into cells and can lead to incorporation of the ribosome-inactivating protein into viral particles. Still another preferred embodiment of the invention includes a targeting moiety attached to the variants of the ribosome-inactivating protein to target the agent to HIV infectable cells.
- Research Organization:
- Idaho National Laboratory (INL), Idaho Falls, ID (United States); BECHTEL BWXT IDAHO LLC
- DOE Contract Number:
- AC07-94ID13223; AC07-99ID13727; AC07-05ID14517
- Assignee:
- Battelle Energy Alliance, LLC (Idaho Falls, ID)
- Patent Number(s):
- US 7,018,633
- Application Number:
- 10/618560
- OSTI ID:
- 880117
- Country of Publication:
- United States
- Language:
- English
Similar Records
Plasmids encoding therapeutic agents
Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex